Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,363
Recruiting: 3,965
Ph III recruiting: 535
Growth YoY: +10.3%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,404)

clinicaltrialsPublishedShowing 401–450 of 534 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05544552	Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301)	active not recruiting	Phase 1 / Phase 2	310	Tyra Biosciences, IncINDUSTRY	4	Jan 12, 2026	clinicaltrials
NCT05902520	Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors(ACT)	active not recruiting	Phase 1	18	AgonOx, Inc.INDUSTRY